ABBV-932

Small molecule

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Other / comorbidity
NCT07220460 · AbbVie
2025-09-30 – 2027-04 · Bipolar I or II Disorder
What this study did
NCT06605599 · AbbVie
2024-10-15 – 2025-12-10 · Bipolar I Disorder, Bipolar II Disorder
What this study did
Phase 1 (7)
Other / comorbidity
NCT06953934 · AbbVie
2026-05-04 – 2026-09-14 · Healthy Volunteer
What this study did
NCT06849791 · AbbVie
2025-02-26 – 2026-05-08 · Healthy Volunteer
What this study did
NCT07024797 · AbbVie
2025-08-21 – 2025-12-08 · Healthy Volunteer
What this study did
NCT06300580 · AbbVie
2024-08-21 – 2025-05-26 · Healthy Volunteers
What this study did
NCT06024239 · AbbVie
2023-08-31 – 2025-03-04 · Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
What this study did
NCT05738850 · AbbVie
2023-02-15 – 2024-05-31 · Generalized Anxiety Disorder (GAD), Healthy Participants
What this study did

Competitive landscape

Other Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) drugs

Cariprazine (QLM1016). Compare all 2 Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) drugs

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Bipolar Depression: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ABBV-932: this drugStage not on recordSmall moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptornot yet gradedNo reviewed efficacy summary in this indication
LurasidoneApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (QLM1016)
Phase 3(overall)
Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 receptor (partial agonist)
not yet graded(overall)
No reviewed efficacy summary in this indication
D-Cycloserine / Lurasidone (NRX-101)Phase 3Small moleculeNMDA receptor (glycine site) + dopamine/5-HT receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ABBV-932 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Generalized Anxiety Disorder (GAD)Recruiting
Est. primary completion 2026-11 · NCT06846320 · CT.gov ↗
What to watch
2027 (2)
February 2027 (1)
Phase 1Bipolar DisorderRecruiting
Est. primary completion 2027-02 · NCT07071532 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Bipolar I or II DisorderActive not recruiting
Est. primary completion 2027-03 · NCT07220460 · CT.gov ↗
What to watch

See the full readout calendar ↗